(NASDAQ: NEUP) Neuphoria Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.83%.
Neuphoria Therapeutics's earnings in 2025 is -$1,806,190.On average, 1 Wall Street analyst forecast NEUP's earnings for 2025 to be -$2,740,962, with the lowest NEUP earnings forecast at -$2,740,962, and the highest NEUP earnings forecast at -$2,740,962. On average, 1 Wall Street analyst forecast NEUP's earnings for 2026 to be -$3,250,500, with the lowest NEUP earnings forecast at -$3,250,500, and the highest NEUP earnings forecast at -$3,250,500.
In 2027, NEUP is forecast to generate -$2,126,003 in earnings, with the lowest earnings forecast at -$2,126,003 and the highest earnings forecast at -$2,126,003.